Synthetic Cannabinoid K2 Overdoses Are Rampant. Here’s Why.
Ashley Yeager | Aug 17, 2018
NIDA pharmacologist Michael Baumann explains how “unscrupulous vendors” hijacked compounds used in neuroscience and turned them into dangerous drugs.
The UK Pharmaceutical Industry Braces for Brexit
The UK Pharmaceutical Industry Braces for Brexit
As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.
As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.
More Vaccinations, Experimental Drugs as Potential Ebola Contacts Rise
Sukanya Charuchandra | May 30, 2018
The World Health Organization predicts the number of cases in Democratic Republic of Congo will rise up to 300 by July.
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
Diana Kwon | May 29, 2018
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.
FDA Approves Drug to Ease Symptoms of Opioid Withdrawal
Catherine Offord | May 17, 2018
Lucemyra is the first non-opioid drug to be approved in the U.S. specifically for this purpose.
Research Scandal Involving Popular Heart Drug Engulfs Three More Papers
Alison McCook, Retraction Watch | May 4, 2018
The scientists involved have hired lawyers to fight the conclusions of a recent investigation into some studies of Diovan in Japan.
Researchers Getting Smarter About Pairing Cancer Treatments
Anna Azvolinsky | Apr 1, 2018
Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful.
European Medicines Agency to Move to Amsterdam
Shawna Williams | Nov 20, 2017
A coin toss decides the agency’s post-Brexit home once it departs from London.